Magic mushrooms may effectively treat depression by 'rebooting' the activity of key brain circuits in patients suffering from the disorder, a study claims.
Magic mushrooms may effectively treat depression by ‘rebooting’ the activity of key brain circuits in patients suffering from the disorder, a study claims. Researchers from Imperial College London in the UK used psilocybin – the psychoactive compound that occurs naturally in magic mushrooms – to treat a small number of patients with depression in whom conventional treatment had failed. They found that patients taking psilocybin to treat depression showed reduced symptoms weeks after treatment. The study, published in the journal Scientific Reports, showed patient-reported benefits lasting up to five weeks after treatment.
Researchers believe the psychedelic compound may effectively reset the activity of key brain circuits known to play a role in depression. Comparison of images of patients’ brains before and one day after they received the drug treatment revealed changes in brain activity that were associated with marked and lasting reductions in depressive symptoms. “We have shown for the first time clear changes in brain activity in depressed people treated with psilocybin after failing to respond to conventional treatments,” said Robin Carhart-Harris, Head of Psychedelic Research at Imperial, who led the study. “Several of our patients described feeling ‘reset’ after the treatment and often used computer analogies. For example, one said he felt like his brain had been ‘defragged’ like a computer hard drive, and another said he felt ‘rebooted’,” Carhart-Harris said.
“Psilocybin may be giving these individuals the temporary ‘kick start’ they need to break out of their depressive states and these imaging results do tentatively support a ‘reset’ analogy. Similar brain effects to these have been seen with electroconvulsive therapy,” said Carhart-Harris. In the trial, the first with psilocybin in depression, 20 patients with treatment-resistant form of the disorder were given two doses of psilocybin (10 milligrammes and 25 mg), with the second dose a week after the first. Nineteen of these underwent initial brain imaging and then a second scan one day after the high dose treatment.
Researchers used two main brain imaging methods to measure changes in blood flow and the crosstalk between brain regions, with patients reporting their depressive symptoms through completing clinical questionnaires. Immediately following treatment with psilocybin, patients reported a decrease in depressive symptoms – corresponding with anecdotal reports of an ‘after-glow’ effect characterised by improvements in mood and stress relief. Functional magnetic resonance imaging (MRI) imaging revealed reduced blood flow in areas of the brain, including the amygdala, a small, almond-shaped region of the brain known to be involved in processing emotional responses, stress and fear.